-

Thermo Fisher Scientific Opens Customer Experience Center for Battery Manufacturing in Seoul

New center provides global battery producers with convenient access to metrology and quality control technologies

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Battery Customer Experience Center in Seoul, South Korea. The advanced facility will assist battery manufacturers in driving innovative solutions that support the United Nations Sustainable Development Goal of providing access to affordable, reliable, sustainable and modern energy for all people by 2030. It also will serve as a global hub for clean energy and battery manufacturing applications, product information and education. The new center will accelerate the development of the next generation of environmentally friendly energy solutions that reduce the world’s reliance on fossil fuels, in line with Thermo Fisher’s company mission to enable its customers to make the world healthier, cleaner and safer.

The center will provide international battery manufacturers with access to the latest metrology and quality control (QC) technologies from Thermo Fisher, bringing together multiple state-of-the-art solutions in one demonstration environment, including the Thermo Scientific™ LInspector™ Measurement and Control System, which supports inline lithium-ion battery QC. In addition, the facility is staffed with applications experts in the fields of material characterization, extrusion, rheology, inline thickness and basis weight metrology and product inspection, offering manufacturers one-stop access to Thermo Fisher’s extensive analytical instrument expertise.

Miguel Faustino, president of chemical analysis at Thermo Fisher Scientific, said, “We are thrilled to be opening our Battery Customer Experience Center, which will help address the current manufacturing challenges facing the lithium-ion battery industry, starting from the highest level of technology development. The center will contribute to the resilience of the sector, by giving producers the knowledge and skills to address evolving needs.”

Due to its central location, the Seoul facility will act as a base from which Thermo Fisher can support battery innovation and production in key end markets, such as China. The hub will also provide a valuable information exchange for joint learning in important areas of energy storage, enabling Thermo Fisher to assist the many manufacturers and end customers it is already working alongside to expand their offerings to a wider consumer base.

Moonsoo Park, PhD., research fellow at LG Energy Solutions, said, “The opening of battery-focused customer experience center is welcomed, and we look forward to collaborating with Thermo Fisher. We expect to shape more effective verification, as well as application processes, for new, cutting-edge electrode measurement technologies in the future.”

To learn more about Thermo Fisher’s extensive battery metrology portfolio, visit: www.thermofisher.com/battery-solutions

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Ellen James
Thermo Fisher Scientific
Ellen.James@thermofisher.com
+1 (206) 348-4954

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Ellen James
Thermo Fisher Scientific
Ellen.James@thermofisher.com
+1 (206) 348-4954

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom